Vinge has advised Cellink AB (publ) in connection with the acquisition of all shares in cytena GmbH. cytena is a life science company which focuses on single cell technologies.
Cytena was established in 2014 from the Institute for Microsystems Technology at the University of Freiburg and primarily sells solutions for the handling of biological cells. The purchase price amounts to MEUR 30.25, corresponding to MSEK 323, and is paid with 1/3 in cash and 2/3 in newly issued Cellink shares. Cellink will convene an extraordinary general meeting which will resolve upon the directed issue of shares to the sellers of cytena.
Vinge’s team primarily consisted of Anders Strid, Daniel Lennartsson Anderås, Alexander Lindeberg and Adam Loewenstein.
